The influence of MRP2, MDR1 and OATP1B3 polymorphism on telmisartan's pharmacokinetics and pharmacodynamics.

Trial Profile

The influence of MRP2, MDR1 and OATP1B3 polymorphism on telmisartan's pharmacokinetics and pharmacodynamics.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Hypertension
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 08 Jan 2012 Actual initiation date changed from (1 Jun 2010) to (1 May 2010 ) as reported by Chinese Clinical Trial Register.
    • 21 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top